|
Match
|
Document |
Document Title |
|
|
US20120308652 |
ORAL FORM OF ADMINISTRATION COMPRISING ENTECAVIR
The invention relates to pharmaceutical formulations, preferably in the form of an oral dosage form, for the treatment of chronic hepatitis-B virus infections, containing micronised Entecavir, and...
|
|
|
US20120135961 |
USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS
The present invention relates to the use of compounds, in which the pharmacophores of quinolone and oxazolidinone are chemically linked together through a linker that is stable under physiological...
|
|
|
US20110160162 |
PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS
Disclosed are prodrugs of A2B adenosine receptor antagonists, and their use in treating mammals for various disease states.
|
|
|
US20120295919 |
ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS
Provided are opioid receptor antagonists represented by the formula (I) where R, Y3, R1, R2, R3, R4 and R5 are as defined herein.
|
|
|
US20110034495 |
Method of Modulating Stress-Activated Protein Kinase System
A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety, being inhibitors of p38 MAP kinase, are...
|
|
|
US20110288105 |
ELTOPRAZINE FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIA
The present invention relates to the treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition may arise as a consequence of long-term treatment with L-DOPA therapy in...
|
|
|
US20110136797 |
CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR
Certain cyclopropyl amines are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.
|
|
|
US20120184556 |
SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS
Disclosed are substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mGluR4 potentiators.
|
|
|
US20110172243 |
USE OF AZAPERONE FOR REDUCING ANTIBIOTIC USAGE
The present invention relates to a method for the reduction of antibiotic usage in animals through the use of orally administered azaperone.
|
|
|
US20120315217 |
INVERSE AGONISTS AND NEUTRAL ANTAGONISTS FOR THE TSH RECEPTOR
TSHR inverse agonists and neutral antagonists that are useful for treating Graves' orbitopathy, Graves' hyperthyroidism and/or thyroid cancer.
|
|
|
US20120028907 |
METHODS FOR IDENTIFICATION OF TUMOR PHENOTYPE AND TREATMENT
The disclosure relates to methods for identifying a tumor as an E2F-responsive gene over-expressing (ERGO) tumor, methods of determining the likelihood that an ERGO tumor patient will survive to a...
|
|
|
US20110318345 |
NASAL DELIVERY
substances and the nasal administration thereof, in particular as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, in particular the posterior region of...
|
|
|
US20120148660 |
CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR
The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.
|
|
|
US20110086818 |
METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITUS
The invention features methods, compositions, and kits for selective inhibition of pain-and itch sensing neurons (nociceptors and pruriceptors) by drug molecules of small molecule weight, while...
|
|
|
US20130123283 |
METHODS AND COMPOSTIONS FOR TREATING PAIN
The present application relates to compounds and methods for treating pain, incontinence and other conditions.
|
|
|
US20120064181 |
P2X3 Receptor Antagonists for Treatment of Pain
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or...
|
|
|
US20120015052 |
P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or...
|
|
|
US20110206783 |
P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or...
|
|
|
US20110003822 |
P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or...
|
|
|
US20110044898 |
TRANSLOCATOR PROTEIN LIGANDS
The present invention relates to compounds and methods for imaging translocator protein (18 kDa) (TSPO) expression in a subject. This invention also relates to compounds and methods for the...
|
|
|
US20120259154 |
In Vivo Immunomagnetic Hyperthermia Platform for Any Cell or Virus Having a Target Surface Receptor
The invention is a nano-entity conjugate for use in an in vivo immunomagnetic hyperthermia system for the detection and treatment of any cell or virus having a target surface receptor which...
|
|
|
US20110201602 |
PROTEIN KINASE MODULATORS AND METHOD OF USE
The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating...
|
|
|
US20110244486 |
METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES
Methods, assays and compositions for the diagnosis and treatment of diabetes, in which the glutamate transporters and/or receptors expressed in pancreatic islet cells are used as therapeutic...
|
|
|
US20110213145 |
Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners
The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with...
|
|
|
US20110183995 |
ELTOPRAZINE FOR SUPPRESSION OF L-DOPA INDUCED DYSKINESIAS
This invention relates to the use of the drug Eltoprazine for combating dyskinesias arising from chronic Levodopa (L-DOPA) therapy in patients suffering from Parkinson's disease.
|
|
|
US20110230441 |
STABLE BORTEZOMIB FORMULATIONS
Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid...
|
|
|
US20120121508 |
RADIOLABELED CGRP ANTAGONISTS
The present invention is directed to radiolabeled CGRP receptor antagonists which are useful for the quantitative imaging of CGRP receptors in mammals.
|
|
|
US20110110914 |
METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS
Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.
|
|
|
US20120101427 |
NOVEL PHOTOSENSITIZER FORMULATIONS FOR ORAL ADMINISTRATION
The present invention provides novel drug formulations for oral administration for diverse medical applications including anticancer, antimetastatic, antibacterial, antifungal, antiprotozoic,...
|
|
|
US20120277180 |
Cofactors and Methods for Use for Individuals
Provided herein are methods and systems for identifying one or more cofactors such as vitamins for individuals based on the genetic makeup of the individual by detecting the presence or absence of...
|
|
|
US20110144338 |
METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS
Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided...
|
|
|
US20120141471 |
Methods of Inhibiting Metastasis from Cancer
The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or...
|
|
|
US20110280808 |
Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of...
|
|
|
US20110256064 |
Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of...
|
|
|
US20120148690 |
SKIN BARRIER FUNCTION RECOVERY ACCELERATOR
A novel skin barrier function recovery acceleration method and accelerator are provided. The present invention provides a skin barrier function recovery accelerator that comprises a TRPA1 agonist...
|
|
|
US20130090345 |
Synthetic Mimetics Of Host Defense And Uses Thereof
The present invention provides arylamide compounds and methods of making and using them as antibiotics.
|
|
|
US20110071167 |
METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)
The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing,...
|
|
|
US20120329661 |
Isotope Labeling-Assisted Quantification (iLAQ) of Biological Compounds
The present invention relates to a plurality of isotopically labeled compounds (“tag isotopomers”) and individual labeled compounds, which are useful for labeling samples of analytes, such as bio...
|
|
|
US20130052280 |
USE OF THEBROMINE FOR LOWERING CENTRAL BLOOD PRESSURE
The use of theobromine for lowering central blood pressure and/or lowering central pulse pressure in humans and derived benefits, and compositions comprising theobromine.
|
|
|
US20110081482 |
PHOTOCHROMIC NAPHTHOPYRANS HAVING A DOUBLE-BRIDGED TERPHENYL SUB-UNIT
The present invention relates to photochromic naphthopyrancs having a double-bridged terphenyl sub-unit, and to the use thereof in plastics of all types, particularly for ophthalmic purposes.
|
|
|
US20100307378 |
CARBAMATE-METHACRYLATE MONOMERS AND THEIR USE IN DENTAL APPLICATIONS
The present invention relates, generally, to monomers containing carbamate-methacrylates or derivatives of carbamate-methacrylates, processes for making the monomers, and compositions comprising...
|
|
|
US20120039913 |
Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders
The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.
|
|
|
US20110124657 |
METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER
The present invention relates to compounds having pharmacological activity towards the 5-HT7 receptor; to a method for identifying them as 5-HT7 ligands, especially as agonists, by using a...
|
|
|
US20120196847 |
6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment...
|
|
|
US20120077979 |
6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment...
|
|
|
US20130018040 |
Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases
Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii (T. gondii) and for the treatment of cryptosporidiosis, caused by the...
|
|
|
US20120252818 |
HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME
The present subject matter relates to a compound represented by the general formula (I) or (I′) or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one o...
|
|
|
US20110319516 |
RELEASE AGENT PARTITION CONTROL IN IMPRINT LITHOGRAPHY
Release agents with increased affinity toward nano-imprint lithography template surfaces interact strongly with the template during separation of the template from the solidified resist in a...
|
|
|
US20120196883 |
SELECTIVE CALCIUM CHANNEL ANTAGONISTS
The present invention relates to compositions and methods for the treatment and/or prevention of neurodegenerative disorders, e.g., Parkinson's disease (PD). In particular, the present invention...
|
|
|
US20110112058 |
NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER
Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The...
|